Safety setback for Pfizer, Lilly pain drug should have Regeneron and Teva feeling nervous

Pfizer and Eli Lilly last week reported their experimental pain drug tanezumab increased rates of osteoarthritis and other skeletal side effects in a Phase 3 trial that showed only limited pain-relief benefit when compared to non-steroidal anti-inflammatory drugs, or NSAIDs.